Olaris
Olaris, Inc. is a data-driven precision medicine company founded in 2014, leveraging metabolomics and machine learning to develop in vitro diagnostics that optimize treatments and patient outcomes. Their core technology, Olaris®, provides precise insights into an individual's healthcare future by analyzing biomarkers such as metabolites. The company aims to remove guesswork from medicine by identifying "biomarkers of response" (BoRs) to determine which patients will benefit from specific therapies, thereby optimizing treatment effectiveness, reducing adverse events, and improving healthcare system efficiency. Olaris has developed diagnostics for oncology, transplant, and neurodegeneration, with a notable product being myOLARIS™-KTdx, a non-invasive urine-based assay for immune status assessment post-kidney transplant that has received a PLA code from the AMA.
Olaris
Olaris, Inc. is a data-driven precision medicine company founded in 2014, leveraging metabolomics and machine learning to develop in vitro diagnostics that optimize treatments and patient outcomes. Their core technology, Olaris®, provides precise insights into an individual's healthcare future by analyzing biomarkers such as metabolites. The company aims to remove guesswork from medicine by identifying "biomarkers of response" (BoRs) to determine which patients will benefit from specific therapies, thereby optimizing treatment effectiveness, reducing adverse events, and improving healthcare system efficiency. Olaris has developed diagnostics for oncology, transplant, and neurodegeneration, with a notable product being myOLARIS™-KTdx, a non-invasive urine-based assay for immune status assessment post-kidney transplant that has received a PLA code from the AMA.
TL;DR
Core focus: Metabolomics + machine learning to develop biomarkers and in vitro diagnostics
Flagship test: myOLARIS-KTdx, a non-invasive urine-based assay for kidney transplant surveillance
Headquarters: Framingham, Massachusetts
Founding year (site): 2014
Reported total funding: ~$29M
Company Overview
Problem Domain
Improving treatment selection and monitoring through metabolomics-derived biomarkers and diagnostics.
Founded
2014
Industry
Biotechnology
Funding Track Record
Investor Signal
“Backed by strategic and venture investors including LabCorp, Bruker, Alumni Ventures, Innospark Ventures, and the Michael J. Fox Foundation”